Brightseed launches agentic AI to speed bioactives discovery from weeks to days
Brightseed has released Hummingbird, an agentic AI platform that lets product developers and scientists query a proprietary database of natural compounds and get actionable recommendations in seconds instead of weeks. The startup built the product by layering AI agents on top of Forager, its existing bioactives discovery platform.
The move targets a specific bottleneck: discovery work at food and nutrition companies remains manual and slow. Before Hummingbird, Brightseed's team would spend weeks researching compounds, producing reports, and waiting for customers to digest findings before responding with follow-up questions.
From manual research to instant answers
With Hummingbird, a product developer can ask a question in plain language-say, "I need a compound to help women aged 35-55 fall asleep"-and receive compound recommendations, relevant biomarkers, dosage information, and supporting scientific evidence within minutes.
One customer reported that a PhD scientist completed in two weeks what previously took six months, according to Lee Chae, Brightseed's cofounder and CEO.
The platform goes beyond basic research. It identifies which product formats (beverages, tablets, gummies) suit specific compounds based on dosage. It flags potential marketing claims, compares concepts to existing products, and surfaces intellectual property considerations for legal and business teams.
Why generic AI tools don't work
A chief executive from a major nutrition company tested Hummingbird against ChatGPT, Claude, and Gemini with the same questions. Brightseed's system delivered more answers with greater detail and specificity. When asked which insights were more actionable, the executive's team chose Brightseed's recommendations.
The difference comes down to data. Hummingbird pulls from years of proprietary research Brightseed has built-connections between natural compounds, biological pathways, and human health outcomes. Generic large language models have no access to this specialized knowledge.
Scale-up and sourcing decisions
Hummingbird can also evaluate how to manufacture compounds at commercial scale. For some bioactives, established botanical supply chains exist. For others, the platform assesses whether extraction, precision fermentation, biotransformation, or chemical synthesis makes sense.
The system does this by understanding the metabolic pathways plants use to produce compounds, then translating those pathways into production blueprints for biomanufacturing.
Rapid agent rollout planned
Brightseed plans to release specialized agents quarterly. A "white space" agent (now in alpha testing) helps identify gaps in the market. A claims agent launches in Q2. The roadmap includes formulation, scale-up, and market agents.
The platform offers three pricing models: subscription access, data generation using a customer's proprietary libraries, and human expert consulting for formulation, validation study planning, and contract research organization management.
Early traction
Hummingbird entered test mode in February 2026. Brightseed has signed two customers and is contracting with several more expected to close in Q2. The company said this puts it nearly at its annual customer target after four months in market.
Some customers are already using Hummingbird to identify bioactives that might mimic GLP-1 activity or trigger its production-a sign of where the nutrition industry's attention has turned.
Learn more: AI for Product Development and Generative AI and LLM resources for professionals using these tools.
Your membership also unlocks:
